Impact of Ruxolitinib on Myelofibrosis Patients Post Allogeneic Stem Cell Transplant—A Pilot Study

In an effort to further understand the feasibility and toxicity of ruxolitinib in the setting of allogeneic stem cell transplant (alloSCT) among patients with myelofibrosis, this retrospective pilot study demonstrated improved outcomes among those patients who received the drug both before and after alloSCT.

British Journal of Haematology